Recent News

• 07.08.2026 - Ovid Therapeutics Strengthens Executive Leadership Team to Support Continued Pipeline Progress and Next Phase of Development
• 06.04.2026 - Ovid Therapeutics to Participate in Upcoming Investor Conferences
• 06.03.2026 - Ovid Therapeutics Appoints Leading Physician-Scientist and Biotech Innovator Anna Greka, M.D., Ph.D., to Board of Directors
• 04.08.2026 - Ovid Therapeutics to Host Potassium-Chloride Co-transporter 2 (KCC2) Deep Dive R&D Event on Tuesday, April 14
• 03.18.2026 - Ovid Therapeutics Announces New OV329 Data and Indication Expansion, Phase 1 Clearance for OV4071, and Reports Fourth Quarter and Full Year 2025 Financial Results
• 10.03.2025 - Ovid Therapeutics Announces Pricing of Private Placement Totaling up to $175 Million in Gross Proceeds
• 10.03.2025 - Ovid announces positive topline results for the next-generation GABA-aminotransferase inhibitor, OV329, that demonstrate strong inhibitory activity and a potential best-in-category safety profile
• 09.26.2025 - Charles Carter
• 03.03.2025 - Ovid Therapeutics Appoints Pioneering Industry Leader Dr. Stelios Papadopoulos to Board of Directors
• 02.27.2025 - Ovid Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

Recent Filings

• 07.08.2026 - 8-K Current report
• 07.08.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 06.17.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.17.2026 - 3 Initial statement of beneficial ownership of securities
• 06.11.2026 - 8-K Current report
• 06.03.2026 - 8-K Current report
• 05.15.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 05.15.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 05.15.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 05.15.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors